Meeting Minutes October 9, 2001, Conference Call Philip Morris/Covance Page 1 of 2

Participants

Philip Morris

Jan Oey Georg Schepers

Covance

John Allinson Mark Bentley Mel Feit Mike Klawikowski Keith Phillips Sharon Pochron Jill Schultz

The following is a summary of the items discussed:

NNK Metabolites in Urine

Sample analysis is in progress with a throughput of approximately 50 samples/week. It is estimated that sample analysis will be completed by mid Nov.

Acetonitrile in Blood and Exhalate

AcN in Blood – Sample analysis is complete with the exception of reassays. Reassays will be completed by 10/17/01. The validation report was sent to Philip Morris for review on 10/02/01.

AcN in Exhalate – Sample analysis will begin the week of 10/15/01, following the installation of a new instrument. The validation report will be sent to Philip Morris for review by 10/10/01.

Nicotine and Metabolites in Urine

Glucuronide validation run was repeated due to a malfunctioning water bath. The validation will be completed this week and data will be sent to PM for review by 10/15.

Hemoglobin Adducts

Sample analysis is in progress. It is estimated that sample analysis will be completed by early Nov.

11-dehydrothomboxane B2 in Urine and 8-Epi-Prostaglandin F2 Alpha in Urine

Sample analysis is in progress and should be completed by mid Nov.

Malondialdehyde in Plasma and Urine

Urine - Sample analysis is complete. Data are ready to be sent to CCLS.

Plasma - Validation will be completed this week and data will be sent to PM for review by 10/02.

Caffeine and Metabolites in Urine

Sample analysis is in progress. Reassays will be completed by 10/12. S. Pochron mentioned again that there are 30 samples with values below the LLOQ for 1-methylxanthine, AFMU, or 1,7-dimethyluric acid. If no value is reported the ratio can not be determined.

ACTION: J. Oey/B. Nelson to discuss internally and report back to Covance.

October 9, 2001 Minutes Page 2 of 2

Next Meeting

Tuesday, October 23, at 9:00 am CT/10:00 am ET

Passcode: SPD Leader: Jill Schultz

Dial-in information will be provided in a separate email.